AB Science SA: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
AB Science SA Announces Launch of a Phase 3 Clinical Trial in Alzheimer's Disease
AB Science SA announced the launch of a phase 3 clinical trial in the treatment of Alzheimer's disease with masitinib, as well as the recruitment of the first patients in this study in several countries. This is an international, multicenter, randomized (1:1:1 ratio), double-blind, placebo controlled, three parallel group phase 3 study to compare the efficacy and safety of masitinib at two different doses in the treatment of patients with mild to moderate Alzheimer's disease. This study, for which recruitment has started in Europe and other countries, will enroll approximately 400 patients.
Latest Developments for Ab Science SA
- AB Science SA Passes Futility Analysis in Pivotal Clinical Study in Mastocytosis
- AB Science SA Announces Positive Results of Amyothropic Lateral Sclerosis Efficacy Experiments with Masitinib
- AB Science SA and Skuldtech Announce the Identification of New Predictive Markers for Pancreatic Cancer Survival Associated with Masitinib Treatment
- AB Science SA Announces that European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec resistant Gastro-Intestinal Stromal Tumor
- Share this
- Digg this